This document outlines details of PBS-subsidised imatinib, dasatinib, nilotinib, ponatinib and asciminib for patients with chronic myeloid leukaemia (CML).
For details on how to process a PBS Authority, see Processing Complex Authority Required Listings.
On this page:
Imatinib, dasatinib and nilotinib quick reference
Ponatinib quick reference
Asciminib quick reference
Imatinib, dasatinib and nilotinib quick reference
Table 1
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial | Telephone Electronic S85: dasatinib imatinib nilotinib | No | OPA | Not specified | Yes |
Continuing | Streamlined S85: dasatinib imatinib nilotinib | No | N/A | Not specified | N/A |
Ponatinib quick reference
Table 2
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial and repeat initial PB171 form | Written Electronic S85: ponatinib | No | OPA | Must be treated by a: | Yes |
Continuing | Telephone Electronic S85: ponatinib | No | OPA | Must be treated by a: - medical practitioner
- nurse practitioner where patient care is being shared with a medical practitioner and the prescription continues existing therapy with this medicine
| Yes |
Asciminib quick reference
Table 3
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial for patients with T315I PB171 form | Written Electronic S85: asciminib | No | OPA | Must be treated by a: | Yes |
Continuing for patients with T315I PB084 form | Written Electronic S85: asciminib | No | OPA | Must be treated by a: - medical practitioner
- nurse practitioner where patient care is being shared with a medical practitioner and the prescription continues existing therapy with this medicine
| Yes |
Initial for patients without T315I | Telephone Electronic S85: asciminib | No | OPA | Not specified | Yes |
Continuing for patients without T315I | Streamlined S85: asciminib | No | N/A | Must be treated by a: - medical practitioner
- nurse practitioner where patient care is being shared with a medical practitioner and the prescription continues existing therapy with this medicine
| N/A |
Expand all